Nine health-care stocks have more than doubled in price this year, but still have more than 100% upside potential, according to analysts.
Pro screened more than 85,000 firms worldwide for stocks that have risen by 100% so far in 2024. They are all covered by at least five or more analysts, and a have a median price target pointing to more than 100% upside potential over the next 12 months. The Nasdaq-listed stocks are Jasper Therapeutics , Corbus Pharmaceuticals , Rezolute , Trevi Therapeutics , Delcath Systems , Benitec Biopharma , Arcutis Biotherapeutics , Praxis Precision Medicines and Humacyte .
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: